Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

939.78 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,603
Open 939.78
Bid (Size) 943.00 (1)
Ask (Size) 944.78 (1)
Prev. Close 939.78
Today's Range 939.78 - 939.78
52wk Range 434.34 - 945.69
Shares Outstanding N/A
Dividend Yield 0.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Both equities have been incredible growth plays of late. 
Via The Motley Fool
Topics ETFs
Warren Buffett Recommends This Magnificent Index Fund. It Could Turn $500 Per Month Into $986,900
The S&P 500 is a group of businesses that are bound to perform well over time, according to Warren Buffett. 
Via The Motley Fool
Topics Stocks
Exposures US Equities

Performance

YTD
+58.69%
+58.69%
1 Month
+8.65%
+8.65%
3 Month
+23.33%
+23.33%
6 Month
+49.13%
+49.13%
1 Year
+113.88%
+113.88%

More News

Read More
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Via Benzinga
Eli Lilly Announces CFO Change
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Via Benzinga
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
Via AB Newswire
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Via InvestorPlace
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
Via InvestorPlace
Summer 2024 Snapshot Of The S&P 500's Market Cap
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
Via InvestorPlace
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
Via The Motley Fool
Exposures Product Safety
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Via Investor's Business Daily
A $2.5 Trillion Opportunity In The Biotech Industry
Via Talk Markets
Facebook Parent Meta Platforms Among 4 Hot Stocks At All-Time Highs: Look For The Best Stocks On These IBD Lists
Via Investor's Business Daily
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.